Unknown PHASE2 INTERVENTIONAL 1-arm NCT05298020

Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer

A Single-arm Phase II Study of Envafolimab Combined With Endostar and Nab-paclitaxel Plus Gemcitabine for First-line Treatment of Advanced Pancreatic Cancer

Sponsor: The Affiliated Hospital of Xuzhou Medical University

Conditions Advanced Pancreatic Cancer

Interventions Endostar Envafolimab Gemcitabine Nab paclitaxel

Updated 4 times since 2022 Last updated: Mar 18, 2022 Started: Apr 1, 2022 Primary completion: Dec 1, 2022 Completion: Apr 1, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05298020, this PHASE2 trial focuses on Advanced Pancreatic Cancer and remains ongoing. Sponsored by The Affiliated Hospital of Xuzhou Medical University, it has been updated 4 times since 2022, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Apr 2024 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Not Yet Recruiting → Unknown Status
Apr 2022 — Apr 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

The Affiliated Hospital of Xuzhou Medical University

Data source: The Affiliated Hospital of Xuzhou Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Xuzhou, China